Market Closed -
Toronto S.E.
21:00:00 01/05/2024 BST
|
5-day change
|
1st Jan Change
|
5.05
CAD
|
0.00%
|
|
+4.55%
|
-2.13%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
1,833
|
2,215
|
3,016
|
2,278
|
1,251
|
1,241
|
-
|
Enterprise Value (EV)
1 |
1,833
|
2,215
|
3,016
|
2,278
|
1,251
|
1,241
|
1,241
|
P/E ratio
|
-1,193
x
|
8.05
x
|
6.95
x
|
-
|
-
|
-
|
-
|
Yield
|
6.71%
|
6.35%
|
5.79%
|
-
|
-
|
7.13%
|
7.13%
|
Capitalization / Revenue
|
5.01
x
|
5.93
x
|
8.05
x
|
5.07
x
|
2.46
x
|
2.58
x
|
2.5
x
|
EV / Revenue
|
5.01
x
|
5.93
x
|
8.05
x
|
5.07
x
|
2.46
x
|
2.58
x
|
2.5
x
|
EV / EBITDA
|
7.16
x
|
8.27
x
|
11.3
x
|
7.3
x
|
2.96
x
|
3.68
x
|
3.54
x
|
EV / FCF
|
-
|
11.8
x
|
24.2
x
|
-
|
-
|
621
x
|
40
x
|
FCF Yield
|
-
|
8.51%
|
4.13%
|
-
|
-
|
0.16%
|
2.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
153,623
|
175,831
|
218,394
|
239,748
|
242,507
|
245,759
|
-
|
Reference price
2 |
11.93
|
12.60
|
13.81
|
9.500
|
5.160
|
5.050
|
5.050
|
Announcement Date
|
04/03/20
|
11/03/21
|
14/03/22
|
31/03/23
|
14/03/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
366
|
373.8
|
374.6
|
448.8
|
508
|
481.9
|
495.6
|
EBITDA
1 |
256.1
|
268
|
265.9
|
312
|
423.1
|
337
|
351
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
-1.871
|
314.4
|
434.9
|
64.3
|
-347.7
|
107
|
118
|
Net margin
|
-0.51%
|
84.09%
|
116.09%
|
14.33%
|
-68.44%
|
22.2%
|
23.81%
|
EPS
|
-0.0100
|
1.565
|
1.988
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
188.5
|
124.5
|
-
|
-
|
2
|
31
|
FCF margin
|
-
|
50.43%
|
33.23%
|
-
|
-
|
0.42%
|
6.26%
|
FCF Conversion (EBITDA)
|
-
|
70.34%
|
46.82%
|
-
|
-
|
0.59%
|
8.83%
|
FCF Conversion (Net income)
|
-
|
59.97%
|
28.62%
|
-
|
-
|
1.87%
|
26.27%
|
Dividend per Share
2 |
0.8000
|
0.8000
|
0.8000
|
-
|
-
|
0.3600
|
0.3600
|
Announcement Date
|
04/03/20
|
11/03/21
|
14/03/22
|
31/03/23
|
14/03/24
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q2
|
2023 Q3
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
|
96.37
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
1 |
0.2000
|
0.2000
|
0.2000
|
0.2000
|
0.2000
|
0.1600
|
0.0900
|
0.0900
|
0.0900
|
0.0900
|
Announcement Date
|
14/03/22
|
12/05/22
|
12/08/22
|
15/11/22
|
11/08/23
|
08/11/23
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
189
|
124
|
-
|
-
|
2
|
31
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/03/20
|
11/03/21
|
14/03/22
|
31/03/23
|
14/03/24
|
-
|
-
|
Last Close Price
5.05
CAD Average target price
5.542
CAD Spread / Average Target +9.74% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.13% | 903M | | +4.65% | 56.3B | | -12.10% | 17.83B | | -4.65% | 13.1B | | -17.41% | 5.43B | | +11.39% | 3.34B | | -2.38% | 3.22B | | -5.50% | 3.06B | | -5.70% | 2.79B | | +13.52% | 2.74B |
Healthcare REITs
|